Zacks Investment ResearchWed, 03 Jun 2026 15:11:06 GMTCan AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?AZN+3.92%
BenzingaTue, 02 Jun 2026 18:26:16 GMTAstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer StudyAZN+3.92%
BenzingaMon, 01 Jun 2026 17:55:51 GMTAstraZeneca Sees Encouraging Survival Trend In Liver Cancer TrialAZN+3.92%
Zacks Investment ResearchWed, 27 May 2026 15:01:09 GMTFDA Extends Review Time for AZN's Camizestrant Combo in Breast CancerAZN+3.92%
ForbesTue, 26 May 2026 13:41:18 GMTHow Big Pharma Is Turning Industrial Heat Into A Strategic AssetAZN+3.92%
Zacks Investment ResearchMon, 25 May 2026 16:40:26 GMTAZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid TumorsAZN+3.92%
Zacks Investment ResearchMon, 25 May 2026 16:31:19 GMTAZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast CancerAZN+3.92%
Seeking AlphaSun, 24 May 2026 13:28:51 GMTAstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data WinsAZN+3.92%
Zacks Investment ResearchMon, 18 May 2026 17:31:11 GMTAZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer SettingsAZN+3.92%
Zacks Investment ResearchMon, 18 May 2026 17:01:35 GMTAstraZeneca Gets FDA Nod for New Hypertension Drug BaxfendyAZN+3.92%
BenzingaFri, 01 May 2026 12:20:14 GMTAstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate FaltersAZN+3.92%
CNBCFri, 01 May 2026 09:51:15 GMTAstraZeneca stock falls after FDA panel votes against new cancer drugAZN+3.92%
WSJFri, 01 May 2026 07:56:00 GMTAstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel VoteAZN+3.92%
24/7 Wall StreetThu, 30 Apr 2026 18:24:32 GMTAstraZeneca Is a Buy as More Than 20 Phase III Readouts LoomAZN+3.92%
Seeking AlphaWed, 29 Apr 2026 20:21:41 GMTAstraZeneca PLC (AZN) Q1 2026 Earnings Call TranscriptAZN+3.92%
Seeking AlphaWed, 29 Apr 2026 14:56:21 GMTAstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And HoldAZN+3.92%
Zacks Investment ResearchWed, 29 Apr 2026 14:30:25 GMTAstrazeneca (AZN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesAZN+3.92%
Zacks Investment ResearchWed, 29 Apr 2026 13:21:06 GMTAZN Q1 Earnings and Sales Beat, Key Drugs Offset Generic PressureAZN+3.92%
